18 recruiting, 6 completed, 3 not yet recruiting, 3 unknown. 21 Phase 2, 7 Phase 1, 5 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Locally Advanced: new trials by email Literature Review of Locally Advanced trials Research Report on Locally Advanced
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy - Non-Small Cell Carcinoma of Lung, Locally Advanced | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2026-11-15 | 2026-10-20 |
| Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Iparomlimab and Tuvonralimab (QL1706), Paclitaxel, Cisplatin - Uterine Cervical Neoplasms, Locally Advanced | Phase 2 | Recruiting | Sun Yat-sen University | 103 | 2026-07-01 | 2026-06-12 |
| CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs CUE-101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Yale University | 30 | 2026-05-07 | 2026-07-30 |
| Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas - Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced | Not applicable | Recruiting | BetaGlue Therapeutics SpA | 10 | 2026-02-03 | 2026-02-19 |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) AVZO-103, Combination Agent - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 355 | 2025-10-02 | 2026-10-05 |
| Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer nab-paclitaxel, oxaliplatin, S-1 - Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma | Phase 2 | Not yet recruiting | zhoujing | 35 | 2025-10-01 | 2025-06-12 |
| Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma cabozantinib and nivolumab - Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma | Phase 4 | Recruiting | Centre Francois Baclesse | 83 | 2025-10-01 | 2026-07-14 |
| Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer Cemiplimab, Fianlimab, Radiotherapy - NSCLC, Locally Advanced | Phase 2 | Recruiting | Montefiore Medical Center | 76 | 2025-08-07 | 2026-04-13 |
| A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors Observation arm - Solid Tumor Cancer, Metastatic Solid Tumors | Not yet recruiting | PENG YUAN | 90 | 2025-07-30 | 2025-07-02 | |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) AVZO-1418, Combination Agent 1, Combination Agent 2 - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 480 | 2025-06-04 | 2026-10-16 |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer REC-1245 - Unresectable, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 170 | 2024-11-21 | 2026-08-20 |
| Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors Lattice therapy (LRT) - Cancer, Metastatic Cancer | Phase 2 | Recruiting | University of Cincinnati | 37 | 2024-08-02 | 2026-05-04 |
| PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC standard Radiotherapy, Chemotherapy, Immunotherapy - Stage III Non-small Cell Lung Cancer, Locally Advanced | Phase 2 | Recruiting | TheraOp | 110 | 2024-07-01 | 2025-12-17 |
| Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy CTV omitted or delineated - Non Small Cell Lung Cancer, Locally Advanced | Not applicable | Recruiting | Hubei Cancer Hospital | 134 | 2024-02-08 | 2024-03-15 |
| Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer Radical surgery, Kidney sparing surgery+Postoperative radiotheray - Locally Advanced, Urothelial Carcinoma Ureter | Recruiting | Xuesong Li | 90 | 2023-11-10 | 2023-11-07 | |
| Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer Stereotactic Ablative Body Radiation (SABR), Tumor Treating Fields (TTF) - Pancreas Cancer, Locally Advanced | Not applicable | Recruiting | Baptist Health South Florida | 48 | 2023-09-21 | 2026-01-12 |
| Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer Toripalimab, short-term radiotherapy, Oxaliplatin - Locally Advanced, High-Risk | Not applicable | Unknown | Nanfang Hospital, Southern Medical University | 53 | 2023-07-01 | 2023-07-05 |
| Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer Serplulimab, Carboplatin, Pemetrexed - Locally Advanced, Non-small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2023-03-14 | 2024-09-19 |
| SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer Short-course radiotherapy, Penpulimab, CAPEOX - Rectal Cancer, Locally Advanced | Phase 2 | Recruiting | Ruijin Hospital | 55 | 2023-02-06 | 2025-08-28 |
| The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer Later-line therapy - Pancreatic Cancer, Locally Advanced | Not applicable | Recruiting | Peking Union Medical College Hospital | 100 | 2023-02-01 | 2023-04-12 |
Showing 20 of 32. Sign in to see all of them.
Neoplasm Metastasis (9) · Carcinoma, Non-Small-Cell Lung (7) · Colorectal Neoplasms (4) · Neoplasms (4) · Pancreatic Neoplasms (4) · Rectal Neoplasms (4) · Breast Neoplasms (3) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Lymphoma (2) · Ovarian Neoplasms (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1)
Neoplasms (24) · Neoplasms by Site (22) · Digestive System Diseases (12) · Digestive System Neoplasms (12) · Pathological Conditions, Signs and Symptoms (10) · Neoplastic Processes (9) · Pathologic Processes (9) · Bronchial Neoplasms (8) · Carcinoma, Bronchogenic (8) · Gastrointestinal Diseases (8) · Gastrointestinal Neoplasms (8) · Lung Diseases (8) · Neoplasms by Histologic Type (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8)
Oxaliplatin (5) · Gemcitabine (4) · Radiotherapy (4) · ganitumab (3) · 130-nm albumin-bound paclitaxel (2) · Bevacizumab (2) · Capecitabine (2) · Carboplatin (2) · Cetuximab (2) · Cisplatin (2) · Drug Therapy (2) · Paclitaxel (2) · conatumumab (2) · pembrolizumab (2) · Epirubicin (1)
Amgen (2) · Avenzo Therapeutics, Inc. (2) · Sun Yat-sen University (2) · Association of Research on the Biology of Liver Tumors (1) · Baptist Health South Florida (1) · BetaGlue Therapeutics SpA (1) · Centre Francois Baclesse (1) · Hospital Universitari de Bellvitge (1) · Hubei Cancer Hospital (1) · ImmuneOncia Therapeutics Inc. (1) · Mahidol University (1) · Memorial Sloan Kettering Cancer Center (1) · Montefiore Medical Center (1) · NSABP Foundation Inc (1) · Nanfang Hospital, Southern Medical University (1)
United States (13) · China (10) · Spain (4) · France (3) · Germany (3) · Italy (3) · Poland (3) · South Korea (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2) · Canada (2) · Czechia (2) · Hungary (2)
Amina Mokrani, A/Prof (1) · Chunmei Bai, MD (1) · Dehua Wu, MD (1) · John Hamm, MD (1) · Marc Fellous, MD (1) · Michael Chuong, M.D. (1) · Mouna Ayadi, A/Prof (1) · Nitin Ohri, MD, MS (1) · Norman Wolmark, MD (1) · Nuttapong Ngamphaiboon, MD (1) · Ren Zhao, MD, PHD (1) · Samuel Funt, MD (1)
PMID 18650156, PMID 20065174, PMID 21071270, PMID 2702835, PMID 33862000, PMID 34268711, PMID 37982827, PMID 38071916, PMID 39033189, PMID 40543428, PMID 40932470, PMID 41740031, PMID 41992146